Clinical trial Recruiting at 1 site Interventional Ages 18 to 45 Women only

Identifying insulin-resistant PCOS with LMNA-related lipodystrophy in young women

Official title: Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS)

Run by Assistance Publique - Hôpitaux de Paris · NCT07412028 · Data updated 2026-11-12

We’re testing whether women with a genetic insulin resistance and lipodystrophy differ from women with PCOS by age and BMI matching.

Quick facts

Study typeInterventional
Ages18 Years to 45 Years
SexWomen only
Enrollment81 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations1 site (Paris)
StatusRecruiting
StartedJuly 21, 2026
Main results expectedJanuary 2028
Study endsJanuary 2028
Registry record updatedAugust 10, 2026
Trial IDNCT07412028 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18 to 44 with either a known pathogenic LMNA variant causing lipodystrophy or PCOS diagnosed by Rotterdam criteria.

Probably not a fit

Participants without the specific LMNA lipodystrophy may not experience a direct benefit beyond contributing to knowledge.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This diagnostic case-control study will compare 25 women with a lipodystrophic syndrome due to LMNA gene variants to 50 PCOS patients who are matched by age and BMI. The study uses genetic analysis, biological testing, and imaging to characterize insulin resistance profiles and related factors. The goal is to understand how the insulin-resistant, lipodystrophic condition presents differently from classic PCOS in women of reproductive age. The design aims to help improve differential diagnosis and future management of rare insulin resistance syndromes presenting with hyperandrogenism.

Why it matters

Potential benefit: If successful, the findings could improve early identification and tailored care for women with rare insulin resistance syndromes presenting as PCOS.

How similar studies have gone: Other studies have explored LMNA-related lipodystrophy and PCOS features, but this exact comparative approach is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women aged ≥ 18 years and \< 45 years ;
* Discontinuation of estrogen-progestin therapyfor at least 3 months ;
* Signed informed consent ;
* Social security affiliation.

Case (n=25):

\- Patient with a lipodystrophic syndrome due to a known pathogenic variant of the LMNA gene.

Control (n=50), :

\- patient consulting for polycystic ovary syndrome (PCOS according to the Rotterdam criteria) in day hospital matched on age +/-5 years and BMI+/-5 kg/m2.

Exclusion Criteria:

* \- Severe renal insufficiency (GFR \< 30 ml/min) ;
* Hepato-cellular insufficiency (TP \< 50%) ;
* Taking corticosteroids or antiretrovirals ;
* Menopausal women ;
* Taking estrogen-progestin therapy;
* Diabetic patients on insulin : type 1 diabetes or pancreatectomised patients
* Other known causes of hyperandrogenism (21-hydroxylase block, Cushing's syndrome, ovarian tumor).
* Pregnant woman
* Breastfeeding woman

Where it's running

  • Service Endocrinologie, Hôpital St Antoine
    Paris, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.